DERM Earnings Date: Nov 11, 2026 (Estimated) — Journey Medical Corporation
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
Updated
When is DERM's next earnings date?
Journey Medical Corporation (DERM) is expected to report Q3 2026 earnings on Wednesday, November 11, 2026 at 4:00 PM ET (after market close); the date is an estimate and has not been confirmed by the company. The consensus estimate is EPS of -$0.03 on revenue of $20.3M.
How did DERM do in its last earnings report?
In its most recent report on Aug 12, 2026 (Q2 2026), Journey Medical Corporation posted EPS of -$0.01 versus the -$0.02 estimate, a beat of 50.0%. Revenue was $17.8M against a $18.4M estimate. The stock's 1-day post-earnings move was +3.4%.
How much does DERM stock move after earnings?
DERM beat EPS estimates in 4 of its last 8 reported quarters. Over the last 8 reports the stock moved an average of 13.8% (up or down) in the day after earnings.
About Journey Medical Corporation
Journey Medical Corporation, a pharmaceutical firm established in Scottsdale, Arizona in 2014 (and previously known as Coronado Dermatology, Inc.), is dedicated to the development and market introduction of treatments for skin conditions across the United States. Their product line encompasses key dermatological therapies such as Qbrexza, a medicated cloth wipe for managing primary axillary hyperhidrosis; Accutane, an oral isotretinoin drug for severe, persistent acne; Targadox, an oral doxycycline medication used as an additional treatment for severe acne; Ximino, an oral minocycline drug addressing moderate to severe acne; and Exelderm, offered as a topical cream and solution. Furthermore, the company distributes doxycycline hyclate tablets, minocycline hydrochloride capsules, and sulconazole nitrate cream and solution.
Earnings History
| Date | Period | EPS Est. | EPS Act. | Surprise | Revenue | Result | 1D Δ | 1W Δ | 1M Δ |
|---|---|---|---|---|---|---|---|---|---|
| 2026-08-12 | Q2 2026 | -0.02 | -0.01 | +50.00% | $17.8M | ✅ Beat | +3.42% | +5.91% | +12.44% |
| 2026-05-13 | Q1 2026 | -0.08 | -0.08 | +0.00% | $16.0M | ➖ Inline | +22.35% | +18.88% | +22.16% |
| 2026-03-25 | Q4 2025 | -0.05 | -0.04 | +20.00% | $16.1M | ✅ Beat | -30.01% | -32.06% | -24.60% |
| 2025-11-12 | Q3 2025 | -0.05 | -0.09 | -80.00% | $17.6M | ❌ Miss | -15.31% | -15.75% | -15.53% |
| 2025-08-12 | Q2 2025 | -0.07 | -0.16 | -128.57% | $15.0M | ❌ Miss | -15.11% | -17.21% | -13.99% |
| 2025-03-26 | Q4 2024 | -0.22 | 0.08 | +136.36% | $13.6M | ✅ Beat | -3.58% | +1.63% | +21.66% |
| 2024-11-12 | Q3 2024 | -0.15 | -0.12 | +20.00% | $14.6M | ✅ Beat | -6.05% | -1.83% | -7.16% |
| 2024-08-12 | Q2 2024 | -0.14 | -0.17 | -21.43% | $14.9M | ❌ Miss | +14.22% | +8.29% | +13.51% |
Showing last 8 quarters.
Revenue by segment & region
By segment
Q2 FY26 · $8.5M total
| Segment | Share | Revenue | YoY | Q4 FY24 | Q1 FY25 | Q2 FY25 | Q3 FY25 |
|---|---|---|---|---|---|---|---|
| Qbrexza | 60.4% | $5.1M | -26.4% | $5.7M | $5.2M | $6.9M | $7.4M |
| Accutane | 39.6% | $3.4M | -1.1% | $3.9M | $3.7M | $3.4M | $2.8M |
Source: company filings via FMP. YoY compares the same fiscal period a year earlier.